Ocular implants and methods for delivering ocular implants into the eye

• US 8,425,449 B2
• Filed: 07/09/2010
• Issued: 04/23/2013
• Est. Priority Date: 07/09/2009
• Status: Active Grant

• Current Assignee: Alcon Incorporated
• Original Assignee: Ivantis Inc.
• Inventors: Wardle, John, Schieber, Andrew T., Galt, Kenneth M.
• Primary Examiner(s): DEAK, LESLIE R
• Application Number:
  US12/833,863
• Publication Number:
  US 20110009958A1
• Time in Patent Office: 1,019 Days
• Field of Search: 604/8, 604/9, 606/107, 606/108
• US Class Current: 604/8
• CPC Class Codes: A61F 9/0017 implantable in, or in contact with, the eye, e.g. ocular inserts
• CPC Class Codes: A61F 9/0026 Ophthalmic product dispenser attachments to facilitate positioning near the eye
• CPC Class Codes: A61F 9/00781 Apparatus for modifying intraocular pressure, e.g. for glaucoma treatment drainage implants in general A61M27/002

Abstract

An ocular implant is provided. In some embodiments, the ocular implant includes a body that is curved about a longitudinal central axis and a distal body portion that defines a longitudinal channel including a channel opening. The implant is sized and configured such that the ocular implant assumes an orientation in which the channel opening is adjacent a major side of Schlemm'"'"'s canal when the ocular implant is disposed in Schlemm'"'"'s canal. Methods for delivering ocular implants into Schlemm'"'"'s canal are also provided. Some methods include covering openings in the ocular implant, advancing the implant into Schlemm'"'"'s canal while at least some of the openings are covered, and uncovering the openings while the distal portion of the implant is disposed in Schlemm'"'"'s canal.

Claims

1. An ocular implant adapted to reside at least partially in a portion of Schlemm'"'"'s canal of an eye, the eye having an iris defining a pupil, the implant comprising:

a body having a first major surface, a second major surface, a first lateral extent and a second lateral extent, an aspect ratio of the first lateral malt to the second lateral extent being greater than or equal to two;

the body being curved about a longitudinal central axis so that the first major surface comprises a concave surface and the second major surface comprises a. convex surface;

a distal portion of the body defining a longitudinal channel including a channel opening, the channel opening being disposed diametrically opposite a central portion of the concave surface; and

the body being adapted and configured such that the ocular implant assumes an orientation in which the channel opening is adjacent a. major side of Schlemm'"'"'s canal when the ocular implant is disposed in Schlemm'"'"'s canal.

2. The ocular implant of claim 1 wherein the channel opens away from the pupil when the channel opening is adjacent an outer major side of Schlemm'"'"'s canal, the outer major side being further from the pupil than an inner major side of Schlemm'"'"'s canal.

3. The ocular implant of claim 1 wherein:

the channel has a width and a depth; and

an aspect ratio of the width to the depth is such that the ocular implant assumes an orientation in which the channel opening is adjacent a major side of Schlernm'"'"'s canal when the ocular implant is disposed in Schlemm'"'"'s canal.

4. The ocular implant of claim 3 wherein the aspect ratio of the width to the depth is greater than one.

5. The ocular implant of claim 4 wherein the aspect ratio of the width to the depth is about two.

6. The ocular implant of claim 1 wherein the distal portion of the body extends across an angular span of less than 180 degrees as the body curves about the longitudinal central axis.

7. The ocular implant of claim 1, wherein the body defines additional openings fluidly communicating with the channel and the body of the implant is more than 50% open due to the openings defined by the body,

8. The ocular implant of claim 1 further comprising a therapeutic agent deposited on the body.

9. The ocular implant of claim 8 wherein the therapeutic agent comprises an anti-glaucoma drug.

10. The ocular implant of claim 9 wherein the anti-glaucoma drug comprises a prostaglandin analog.

11. The ocular implant of claim 10 wherein the prostaglandin analog comprises latanprost.

12. The ocular implant of claim 1, wherein the body is curved about a lateral central axis so that a longitudinal axis of the body defines a plane.

13. The ocular implant of claim 12, wherein the body has a lateral radius of curvature extending between the lateral central axis and an outer extent of the body.

14. The ocular implant of claim 13, wherein the lateral radius of curvature is substantially constant.

15. The ocular implant of claim 14, wherein the lateral radius of curvature varies along a length of the body.